

Indoco's clinical research organisation, AnaCipher completes US FDA inspection

Our Bureau, Mumbai

Tuesday, March 11, 2025, 11:30 Hrs [IST]

Indoco Remedies Limited (Indoco), a fully integrated, research-oriented pharmaceutical company, announced that its clinical research organisation, AnaCipher, located at Hyderabad, has completed its 5-day comprehensive US FDA inspection. The on-site inspection was conducted from 3rd March, 2025 to 7th March, 2025, by investigators from Bioresearch Monitoring Programme (BIMO) and Office of Study Integrity & Surveillance (OSIS) of US FDA.

The inspection covered both clinical & bioanalytical phases of three bioavailability and bioequivalence (BA/BE) studies submitted by clients, to the US Food and Drug Administration. The facility received one Form 483 at the end of the inspection, which will be responded within the timeframe.

"This is an exciting step in our journey of excellence and a validation of our adherence to applicable regulations and maintaining the highest standards in delivering quality services to our clients." stated Aditi Kare Panandikar, managing director, Indoco Remedies Limited.

Indoco is a fully integrated, research-oriented pharmaceutical company with a strong global presence. The company's turnover is US\$ 212 million with a human capital of over 6000 employees, including over 400 skilled scientists and field staff who are the strength of the organization.